Insulet Corporation $PODD Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. lessened its holdings in Insulet Corporation (NASDAQ:PODD) by 2.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,091,698 shares of the medical instruments supplier’s stock after selling 43,370 shares during the quarter. Baillie Gifford & Co. owned approximately 2.97% of Insulet worth $645,770,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. True Wealth Design LLC increased its holdings in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH purchased a new position in Insulet in the second quarter valued at approximately $35,000. Quent Capital LLC acquired a new stake in Insulet during the third quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of Insulet during the 2nd quarter worth approximately $51,000.

Insulet Stock Down 3.0%

PODD opened at $271.57 on Friday. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $354.88. The business has a 50 day moving average price of $298.48 and a two-hundred day moving average price of $310.15. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The company has a market cap of $19.10 billion, a PE ratio of 78.72, a P/E/G ratio of 1.56 and a beta of 1.40.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same quarter in the previous year, the company posted $1.08 earnings per share. The company’s revenue for the quarter was up 29.9% compared to the same quarter last year. As a group, research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wolfe Research increased their target price on shares of Insulet from $350.00 to $375.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Rothschild & Co Redburn upped their price objective on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Wells Fargo & Company lifted their target price on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Raymond James Financial boosted their target price on Insulet from $366.00 to $385.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Finally, Jefferies Financial Group raised their price target on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Twenty-one research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $379.10.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.